G. Sottilotta, F. Luise, D. Megalizzi
Abstract
This case report describes the management of a 53-year-old male with moderate hemophilia A and a complex cardiovascular history, including HIV and HCV infections, who experienced a non-Q myocardial infarction requiring dual antiplatelet therapy and percutaneous coronary intervention. The patient was successfully managed with prophylaxis using extended half-life (EHL) recombinant factor VIII (turoctocog alfa pegol) during and after cardiac procedures.
This report highlights the challenges and strategies in balancing bleeding and thrombotic risks in hemophilia patients with cardiovascular comorbidities and discusses the rationale for factor level targets during antithrombotic therapy.
(»Download here full PDF version)
